STOCKHOLM, July 21, 2015 /PRNewswire/ --
Episurf Medical, a cutting edge Swedish medical device technology company has established a UK subsidiary, Episurf Ltd., in line with the company's commercial expansion plans for key European markets.
Episurf Medical has developed the world's first 3D-based patient specific joint resurfacing treatment aimed at providing lasting pain relief and restoring joint mobility. Following a precise 3D modeling of a patient's anatomy, Episurf Medical designs and creates a patient-specific implant, along with surgical instruments, for a safe, simple, fast, reproducible and precise surgery.
(Photo: http://photos.prnewswire.com/prnh/20150721/238720 )
"We have previously announced that a key strategic goal for 2015 is to build a presence in the UK. This market, treatment of knee pain and cartilage damage, represents a significant opportunity for Episurf. In 2014, the UK carried out 100 000 knee replacement operations in 400 hospitals and approximately 190 000 arthroscopic procedures," commented Rosemary Cunningham Thomas, CEO of Episurf Medical.
The first surgeries in the UK were performed in March 2015 at the Rugby Hospital by Professor Tim Spalding. After the second surgery he commented: "The case went exactly to plan, the guide fitted perfectly, allowing minimal necessary exposure. The instrumentation created the ideal socket and the implant fitted with a complete match. Beautifully elegant and well engineered."
Since then Episurf Medical has established a direct sales team in the UK and will be deploying key clinical programs and marketing efforts to accelerate product adoption.
"Our technology has significant scope to provide patients and clinicians with an advanced technology solution for knee pain within a cost effective framework. By offering an on-demand patient-specific production of an all-inclusive one-time-use surgical kit our treatment doesn't require hospitals to keep our products or instruments in stock. I believe that Episurf's treatment goes hand in hand with the UK NHS guidelines for improved outcome at reduced costs," Rosemary Cunningham Thomas continued.
In a recent development program document, the UK NHS has outlined the need to assess how it can improve outcomes at reduced costs through a review of its clinical partnership procurement process (Better_Procurement_Better_Value_Better_Care_:_A_Procurement Development_Programme_for_the_NHS)
Extract: "For example, in the case of orthopaedic hip and knee joints, it is estimated that as much as 40 per cent of the price of joints is associated with 'costs to serve' i.e. consignment stock, instrumentation and sales support staff. These costs are double that are found in other sectors and are further compounded by the variation of choices made by surgeons even in the same hospital. We think the business model by which orthopaedic suppliers sell to the NHS is inefficient, outdated and not in the best interests of either party."
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. http://www.episurf.com.
Share this article